Citigroup’s X4 Pharmaceuticals XFOR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $327K | Buy |
70,112
+34,347
| +96% | +$141K | ﹤0.01% | 4104 |
|
|
2026
Q1 | $148K | Buy |
35,765
+3,433
| +11% | +$12.9K | ﹤0.01% | 4130 |
|
|
2025
Q4 | $129K | Buy |
32,332
+32,300
| +100,938% | +$117K | ﹤0.01% | 4202 |
|
|
2025
Q3 | $109 | Sell |
32
-730
| -96% | -$1.88K | ﹤0.01% | 5804 |
|
|
2025
Q2 | $1.45K | Sell |
762
-3,317
| -81% | -$13.6K | ﹤0.01% | 5382 |
|
|
2025
Q1 | $28.9K | Sell |
4,079
-495
| -11% | -$6.82K | ﹤0.01% | 5015 |
|
|
2024
Q4 | $101K | Buy |
4,574
+405
| +10% | +$6.46K | ﹤0.01% | 4838 |
|
|
2024
Q3 | $83.7K | Buy |
4,169
+2,950
| +242% | +$61.6K | ﹤0.01% | 4850 |
|
|
2024
Q2 | $21.2K | Sell |
1,219
-3,016
| -71% | -$98.6K | ﹤0.01% | 4984 |
|
|
2024
Q1 | $177K | Buy |
4,235
+3,647
| +620% | +$101K | ﹤0.01% | 4071 |
|
|
2023
Q4 | $14.8K | Buy |
588
+586
| +29,300% | +$14.3K | ﹤0.01% | 5085 |
|
|
2023
Q3 | $75 | Sell |
2
-1,220
| -100% | -$53.2K | ﹤0.01% | 5477 |
|
|
2023
Q2 | $71.1K | Buy |
+1,222
| New | +$62.8K | ﹤0.01% | 4422 |
|
|
2021
Q3 | – | Sell |
-1
| Closed | – | – | 6354 |
|
|
2021
Q2 | $0 | Sell |
1
-35
| -97% | -$8.8K | ﹤0.01% | 6438 |
|
|
2021
Q1 | $9K | Sell |
36
-65
| -64% | -$17.1K | ﹤0.01% | 5719 |
|
|
2020
Q4 | $19K | Buy |
101
+75
| +288% | +$14.7K | ﹤0.01% | 6700 |
|
|
2020
Q3 | $5K | Sell |
26
-44
| -63% | -$10.5K | ﹤0.01% | 7053 |
|
|
2020
Q2 | $20K | Sell |
70
-35
| -33% | -$9.58K | ﹤0.01% | 6630 |
|
|
2020
Q1 | $31K | Buy |
105
+26
| +33% | +$7.38K | ﹤0.01% | 6388 |
|
|
2019
Q4 | $25K | Buy |
79
+59
| +295% | +$21.2K | ﹤0.01% | 6824 |
|
|
2019
Q3 | $7K | Sell |
20
-45
| -69% | -$17.8K | ﹤0.01% | 7232 |
|
|
2019
Q2 | $29K | Buy |
65
+52
| +400% | +$26.4K | ﹤0.01% | 6897 |
|
|
2019
Q1 | $6K | Buy |
13
+5
| +63% | +$2.76K | ﹤0.01% | 7394 |
|
|
2018
Q4 | $3K | Sell |
8
-694
| -99% | -$265K | ﹤0.01% | 7471 |
|
|
2018
Q3 | $205K | Buy |
702
+698
| +17,450% | +$296K | ﹤0.01% | 5231 |
|
|
2018
Q2 | $2K | Buy |
4
+1
| +33% | +$3.27K | ﹤0.01% | 7479 |
|
|
2018
Q1 | $14K | Sell |
3
-1
| -25% | -$2.91K | ﹤0.01% | 6923 |
|
|
2017
Q4 | $9K | Buy |
+4
| New | +$10.1K | ﹤0.01% | 7084 |
|
Other funds holding XFOR
BCLSI
PA
SVCM
EAM
DTC
KCM
Citigroup's XFOR Position: Q2 2026 in Review
Citigroup increased its X4 Pharmaceuticals (XFOR) stake by 96% in Q2 2026, buying an estimated $141K and bringing the position to 70,112 shares worth $327K. The position accounts for ﹤0.01% of the portfolio, ranked #4104.
Citigroup first reported a position in XFOR in Q4 2017 and has held it in 28 quarters since. 89 funds tracked by Wall St. Rank hold XFOR as of Q2 2026.
- Citigroup held 70,112 shares of X4 Pharmaceuticals worth $327K as of Q2 2026.
- Citigroup bought 34,347 X4 Pharmaceuticals shares in Q2 2026, an estimated $141K.
- X4 Pharmaceuticals made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #4104 holding.
- Citigroup first reported a position in X4 Pharmaceuticals in Q4 2017 and has held it in 28 quarters since.
- 89 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q2 2026.
Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.